Axsome Therapeutics (AXSM) Stock: Buy, Sell, or Hold?
AXSM - Axsome Therapeutics, Inc
$145.04
-11.03 (-7.07%)
▼
5d:
-7.7%
30d:
-26.01%
90d:
-39.15%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 02, 2026
8d
Get Alerted When AXSM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: AXSM shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: AXSM shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$129.39
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$80.34
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AXSM is currently trading at $145.04, which is considered oversold relative to its 30-day fair value range of $159.93 to $200.91. From a valuation perspective, the stock is trading at a discount (Forward PE: 39.3) compared to its historical average (70.6). Remarkably, the market is currently pricing in an annual earnings decline of 17.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, AXSM is in a strong downtrend. The price is currently testing key support at $143.90. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.1% recently.
Market Sentiment: AXSM scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $280.33 (+93.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AXSM is in a strong downtrend. The price is currently testing key support at $143.90. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.1% recently.
Market Sentiment: AXSM scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $280.33 (+93.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$159.93 -
$200.91
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.4%
Protect Your Profits
Holding AXSM? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.1%)
- BULLISH: Trading 93.3% below Wall St target ($280.33)
- WARNING: Composite score 43/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$159.93 -
$200.91
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$143.90
Resistance Level
$170.80
Current Trend
Strong Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
39.27
Wall Street Target
$280.33
(+93.3%)
Revenue Growth (YoY)
45.5%
Profit Margin
-24.7%
Valuation Discount vs History
-17.8% cheaper
PE vs Historical
39.3 vs 70.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-17.8%
(market-implied from PE analysis)
1-Year Target
$130.54
(-10%)
2-Year Target
$117.48
(-19%)
3-Year Target
$105.73
(-27%)
3-Yr Target (if PE normalizes)
(PE: 39→71)
$190.11
(+31%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 39.3 to 70.6
Stabilization Target:
$260.78
(+79.8%)
PE Expansion Potential:
+79.8%
Share & Embed Analysis
Last updated: October 24, 2026 9:51 AM ET
Data refreshes hourly during market hours. Next update: 10:51 AM
Data refreshes hourly during market hours. Next update: 10:51 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AXSM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 53 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 64 BUY |
|
RYTM
Rhythm Pharmaceuticals I… |
STRONG BUY
18 analysts |
$144 | 75 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$686 | 48 HOLD |
|
IMNM
Immunome Inc |
STRONG BUY
16 analysts |
$35 | 59 HOLD |
Advanced AXSM Option Strategies
Professional options setups generated by AI based on today's AXSM price and gamma walls.
